B. K. O'Connell, D. Gloss and O. Devinsky. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav 70(Pt B)341-348.
M. Bialer, S. I. Johannessen, R. H. Levy, E. Perucca, T. Tomson and H. S. White. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia 58(2)181-221.
This was a report on the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26-29, 2016. 12 drugs in phase I-III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-d-glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE-217, and valnoctamide). Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.
M. Hausman-Kedem and U. Kramer. Efficacy of Medical Cannabis for Treatment of Refractory Epilepsy in Children and Adolescents with Emphasis on the Israeli Experience. Isr Med Assoc J 19(2)76-78. This was a discussion on the use of Cannabis in children with resistance to medication to alleviate epilepsy. In summary they concluded that the good outcome in a significant number of patients, which is not significantly worse than other accepted options for patients with refractory epilepsy, it seems that medical cannabis should be considered a viable treatment option. Further research is warranted